The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study

Abstract

Background: To assess the efficacy of metastasis-directed external beam radiotherapy (MDT) in patients with castration-resistant prostate cancer (CRPC), we conducted a multicenter retrospective study.

Materials and methods: We retrospectively analyzed data from patients with metastatic CRPC treated with MDT between January 2013 and July 2023 across 14 hospitals. Patients who received palliative or local radiation therapy or had insufficient clinical data were excluded. The primary endpoint was the change in prostate-specific antigen (PSA) levels from pre- to post-MDT. Secondary endpoints included overall survival, time to next systemic therapy, PSA progression-free survival, and reduction of target lesions assessed radiographically.

Results: Among 579 patients with metastatic prostate cancer who received radiation therapy, 48 underwent MDT. The median follow-up period was 325 days, and the median patient age was 74 years. Metastasis-directed external beam radiotherapy target sites included bone (n = 34, 70.8%), lymph nodes (n = 11, 22.9%), local recurrence (n = 2, 4.2%), and other sites (n = 1, 2.1%). Of the 48 patients, 30 (62.5%) showed a decrease in PSA levels after MDT, and 20 (41.6%) achieved a PSA reduction greater than 50%. Among the 26 patients who underwent post-MDT radiographic evaluation, 11 (42.3%) demonstrated a reduction in target lesions. Median overall survival, PSA progression-free survival, and time to next systemic therapy for patients with and without a PSA response were 1307 versus 614 days (p = 0.038, log-rank test), 233 versus 98 days (p = 0.014, log-rank test), and 434 versus 450 days (p = 0.273, log-rank test), respectively. The median PSA doubling time was 4.1 months in PSA responders and 1.7 months in nonresponders.

Conclusions: Metastasis-directed external beam radiotherapy resulted in PSA reduction in 62.5% of patients with metastatic CRPC. Metastasis-directed external beam radiotherapy may be a suitable treatment option for patients with a favorable prognosis but may not benefit those with a poor prognosis and short PSA doubling time.

Keywords

Metastasis-directed external beam radiotherapy / Metastatic castration-resistance prostate cancer / Prostate specific antigen

Acknowledgments

None.

Statement of ethics

This study was approved by the ethics committee of the Sapporo Medical University School of Medicine (institutional review board number 352-1064) as well as the ethics committees of each participating hospital. All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participants were given the opportunity to opt-out. No requests to decline participation were submitted during the study.

Conflict of interest statement

The authors declare no conflicts of interest.

Funding source

None.

Author contributions

YS, TS, KH, YK, KK, TT, NM: Study conception and design;

YS, TS, KH, NI, GK, RK, SM, MO, MM, SS, AT, SK, YK, AW, HH, TM: Data acquisition;

YS, TS: Literature research, manuscript writing and manuscript editing;

TS, KH, NM: Manuscript revision;

YS, TS, KH, NM: Data analysis and interpretation;

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3):209-249.

[2] Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007; 13(21):6396-6403.

[3] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368(2):138-148.

[4] Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36(5):446-453.

[5] Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020; 6(5):650-659.

[6] Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials. J Clin Oncol 2022; 40(29):3377-3382.

[7] Tang C, Sherry AD, Haymaker C, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: The EXTEND phase 2 randomized clinical trial. JAMA Oncol 2023; 9(6):825-834.

[8] Francolini G, Allegra AG, Detti B, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A randomized phase II trial (ARTO). J Clin Oncol 2023; 41(36):5561-5568.

[9] Triggiani L, Mazzola R, Magrini SM, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: A multicenter study. World J Urol 2019; 37(12):2631-2637.

[10] Deek MP, Taparra K, Phillips R, et al. Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol 2021; 4(3):447-455.

[11] Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48(3):452-458.

[12] Moyer CL, Phillips R, Deek MP, et al. Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World J Urol 2019; 37(12):2623-2629.

[13] Zhang H, Orme JJ, Abraha F, et al. Phase II evaluation of stereotactic ablative radiotherapy (SABR) and immunity in ¹¹C-choline-PET/CT-identified oligometastatic castration-resistant prostate cancer. Clin Cancer Res 2021; 27(23):6376-6383.

[14] Lee JN, Kim MY, Kang JH, et al. Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer. Investig Clin Urol 2024; 65(2):132-138.

[15] Xu XS, Ryan CJ, Stuyckens K, et al. Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients. Clin Cancer Res 2015; 21(14):3170-3177.

[16] Lin YC, Lin PH, Shao IH, et al. Prostate-specific antigen kinetics effects on outcomes of low-volume metastatic prostate cancer patients receiving androgen deprivation therapy. J Oncol 2021;2021:9648579.

[17] Miyake H, Matsushita Y, Watanabe H, et al. Prognostic significance of time to castration resistance in patients with metastatic castration-sensitive prostate cancer. Anticancer Res 2019; 39(3):1391-1396.

[18] Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 2015; 33(12):1356-1363.

[19] Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate-to high-risk prostate cancer: A systematic review and meta-analysis. Eur Urol 2023; 84(1):36-48.

[20] Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol 2020; 38(17):1963-1996.

[21] Urso L, Filippi L, Castello A, et al. PSMA PET/CT in castration-resistant prostate cancer: Myth or reality? J Clin Med 2023; 12(22):7130.